EUVIMEDEUVIMED entdecken
Crossref

First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease

Alan Santini, Elisa Tassinari, Eleonora Poeta, Manuela Loi, Elisabetta Ciani, Stefania Trazzi, Rebecca Piccarducci, Simona Daniele, Claudia Martini iD, Barbara Pagliarani, Andrea Tarozzi iD, Matteo Bersani und 8 weitere

ACS Chemical Neuroscience · 2024

DOI: 10.1021/acschemneuro.4c00061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Alan Santini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Alzheimer Disease, Glycogen Synthase Kinase 3 beta. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: European Commission, Universit? degli Studi di Torino, Danmarks Frie Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite recent FDA approvals, Alzheimer's disease (AD) still represents an unmet medical need. Among the different available therapeutic approaches, the development of multitarget molecules represents one of the most widely pursued. In this work, we present a second generation of dual ligands directed toward highly networked targets that are deeply involved in the development of the disease, namely, Histone Deacetylases (HDACs) and Glycogen Synthase Kinase 3β (GSK-3β). The synthesized compounds are highly potent GSK-3β, HDAC2, and HDAC6 inhibitors with IC50 values in the nanomolar range of concentrations. Among them, compound 4 inhibits histone H3 and tubulin acetylation at 0.1 μM concentration, blocks hyperphosphorylation of tau protein, and shows interesting immunomodulatory and neuroprotective properties. These features, together with its ability to cross the blood-brain barrier and its favorable physical-chemical properties, make compound 4 a promising hit for the development of innovative disease-modifying agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsAlzheimer DiseaseGlycogen Synthase Kinase 3 betaHumansHistone Deacetylase 6AnimalsNeuroprotective Agentstau ProteinsHistone DeacetylasesPhosphorylationAcetylationHistone Deacetylase 2

Stichwörter der Autor:innen

Alzheimer’s diseaseGlycogen Synthase Kinase 3βHistone DeacetylaseMultitarget DrugsNeuroprotection

Substanzen

Histone Deacetylase InhibitorsGlycogen Synthase Kinase 3 betaHistone Deacetylase 6Neuroprotective Agentstau ProteinsHDAC6 protein, humanHistone DeacetylasesHistone Deacetylase 2

Autor:innen und Institutionen

  • Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.
  • Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.
  • Department of Biomedical and Neuromotor Science, Alma Mater Studiorum-University of Bologna, Piazza di Porta S. Donato, 2, 40126 Bologna, Italy.
  • Department of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy.
  • Department of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.
  • Center for Biopharmaceuticals and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark.

ORCID-Profile: Claudia Martini, Andrea Tarozzi, Francesca Spyrakis, Daniela Danková, Christian A Olsen, Andrea Milelli

Förderung

  • European Commission
  • Universit? degli Studi di Torino
  • Danmarks Frie Forskningsfond
  • Universit? di Bologna
  • Ministero dell'Universit? e della Ricerca
  • Universit? di Pisa

Zitieren

APA

Santini, A., Tassinari, E., Poeta, E., Loi, M., Ciani, E., Trazzi, S., Piccarducci, R., Daniele, S., Martini, C., Pagliarani, B., Tarozzi, A., Bersani, M., Spyrakis, F., Danková, D., Olsen, C. A., Soldati, R., Tumiatti, V., Montanari, S., De Simone, A., & Milelli, A. (2024). First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00061

Vancouver

Santini A, Tassinari E, Poeta E, Loi M, Ciani E, Trazzi S, et al. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00061

BibTeX
@article{Santini2024,
  author = {Santini, Alan and Tassinari, Elisa and Poeta, Eleonora and Loi, Manuela and Ciani, Elisabetta and Trazzi, Stefania and Piccarducci, Rebecca and Daniele, Simona and Martini, Claudia and Pagliarani, Barbara and Tarozzi, Andrea and Bersani, Matteo and Spyrakis, Francesca and Danková, Daniela and Olsen, Christian A and Soldati, Roberto and Tumiatti, Vincenzo and Montanari, Serena and De Simone, Angela and Milelli, Andrea},
  title = {First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease},
  journal = {ACS Chemical Neuroscience},
  year = {2024},
  doi = {10.1021/acschemneuro.4c00061}
}
Kostenlos starten →